Cargando…

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

It has been reported that patients frequently discontinue treatment for erectile dysfunction (ED) with phosphodiesterase type 5 inhibitors (PDE5Is) despite apparently good therapeutic results. Because expectations have been shown to affect patients’ appraisals of many drugs, the purpose of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louizos, Connie C. J., Knight, Peter K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597108/ https://www.ncbi.nlm.nih.gov/pubmed/28975917 http://dx.doi.org/10.3390/pharmacy3040295

Ejemplares similares

Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport(®)) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction—Case Studies
por: Giuliano, Francois, et al.
Publicado: (2019)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
por: Carvalheira, Ana, et al.
Publicado: (2014)

Lifestyle modifications and erectile dysfunction: what can be expected?
por: Maiorino, Maria Ida, et al.
Publicado: (2015)

Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors
por: Bechara, Amado, et al.
Publicado: (2016)

Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil
por: Jannini, Emmanuele A., et al.
Publicado: (2018)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Advanced hydrogels: New expectation for the repair of organic erectile dysfunction
por: Ren, Yan, et al.
Publicado: (2023)

Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis
por: Zhu, Jun, et al.
Publicado: (2020)

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
por: Rosenberg, M T, et al.
Publicado: (2009)

Erectile dysfunction and exosome therapy
por: Feng, Huan, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Dr. Bang-Ping Jiann: PDE5 inhibitors in erectile dysfunction
por: Gao, Lucine M.
Publicado: (2016)

Relationship between Response to PDE5 Inhibitors and Penile Duplex Doppler Ultrasound in Erectile Dysfunction
por: Ogreden, Ercan, et al.
Publicado: (2018)

Neurogenic Erectile Dysfunction. Where Do We Stand?
por: Thomas, Charalampos, et al.
Publicado: (2021)

Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
por: Udeoji, Dioma U, et al.
Publicado: (2014)

The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction
por: Cho, Min Chul, et al.
Publicado: (2019)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Stem-cell therapy for erectile dysfunction
por: Albersen, Maarten, et al.
Publicado: (2013)

Novel Emerging Therapies for Erectile Dysfunction
por: Kim, Soyeun, et al.
Publicado: (2021)

Erectile Dysfunction
Publicado: (2015)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
por: Cota, Jason M., et al.
Publicado: (2021)

Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
por: Sung, Hyun Hwan, et al.
Publicado: (2019)

Regenerative therapies for erectile dysfunction: the influence of direct-to-consumer marketing on patient interest
por: Yang, Shangyang Christopher, et al.
Publicado: (2023)

Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
por: Kiguradze, Tina, et al.
Publicado: (2017)

Regenerative technology for future therapy of erectile dysfunction
por: Ryu, Ji-Kan, et al.
Publicado: (2012)

Traditional Chinese medical therapy for erectile dysfunction
por: Li, Hao, et al.
Publicado: (2017)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
por: Yuan, Jin-Qiu, et al.
Publicado: (2016)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction
por: Wang, Rui, et al.
Publicado: (2022)

AB007. Protein therapy to regenerate erectile tissue for future management of erectile dysfunction
por: Ryu, Ji-Kan, et al.
Publicado: (2018)

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
por: Raheem, Amr Abdel, et al.
Publicado: (2009)

Markers of erectile dysfunction
por: Davies, Kelvin P., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_c29v7uesv35arcc19vkigsd856